Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 1/2020

21.12.2019 | Research Article

Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission

verfasst von: Milena Kovačević, Sandra Vezmar Kovačević, Slavica Radovanović, Predrag Stevanović, Branislava Miljković

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background Drug–drug interactions represent one of the causes of adverse therapy outcomes through deteriorated efficacy or safety. However, the true extent of harm related to drug–drug interactions is not well established due to a lack of recognition and understanding. Objective The aim of this study was to investigate the association of potential drug–drug interactions with patients variables recorded at admission. Setting A cross-sectional correlation study was performed on the Cardiology ward of the University Clinical Hospital Center in Belgrade, Serbia. Method Data were retrospectively obtained from medical records and LexiInteract was used as the screening tool for potential drug–drug interactions. Main outcome measure Clinical and laboratory parameters recorded at the patients admission. Results A total of 351 patient records entered the analysis, with the mean age of 70 ± 10 years. The prevalence of potentially relevant drug–drug interactions was 61% (N = 213). After controlling for patient characteristics, nine potential drug–drug interactions were significantly associated with laboratory values outside the range and five potential drug–drug interactions with inadequate clinical parameter values. Potential drug–drug interactions were associated with abnormalities in blood count, metabolic parameters, electrolyte imbalance and renal function parameters. Association with inadequate control of systolic, diastolic blood pressure, as well as heart rhythm was also shown. Conclusion Drug–drug interactions were associated with patients clinical and laboratory findings. Our findings may assist in the identification of patients with increased likelihood of suboptimal therapy outcomes. Generating evidence through post-marketing drug–drug interactions research would lead to improvement in clinical decision-support systems, increased effectiveness and utilization in everyday clinical practice.
Literatur
1.
Zurück zum Zitat Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201(Suppl 1):S1–7.PubMed Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201(Suppl 1):S1–7.PubMed
2.
Zurück zum Zitat Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–8.PubMed Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–8.PubMed
3.
Zurück zum Zitat Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882–7.PubMed Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012;125:882–7.PubMed
4.
Zurück zum Zitat Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol. 2018;74:819–32.PubMed Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol. 2018;74:819–32.PubMed
5.
Zurück zum Zitat Lin CW, Wen YW, Chen LK, Hsiao FY. Potentially high-risk medication categories and unplanned hospitalizations: a case-time-control study. Sci Rep. 2017;7:41035.PubMedPubMedCentral Lin CW, Wen YW, Chen LK, Hsiao FY. Potentially high-risk medication categories and unplanned hospitalizations: a case-time-control study. Sci Rep. 2017;7:41035.PubMedPubMedCentral
6.
Zurück zum Zitat Patel NS, Patel TK, Patel PB, Naik VN, Tripathi CB. Hospitalizations due to preventable adverse reactions-a systematic review. Eur J Clin Pharmacol. 2017;73:385–98.PubMed Patel NS, Patel TK, Patel PB, Naik VN, Tripathi CB. Hospitalizations due to preventable adverse reactions-a systematic review. Eur J Clin Pharmacol. 2017;73:385–98.PubMed
7.
Zurück zum Zitat Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73:759–70.PubMed Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73:759–70.PubMed
8.
Zurück zum Zitat Aagaard L, Strandell J, Melskens L, Petersen PS, Holme HE. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf. 2012;35:1171–82.PubMed Aagaard L, Strandell J, Melskens L, Petersen PS, Holme HE. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf. 2012;35:1171–82.PubMed
9.
Zurück zum Zitat Hines LE, Murphy JE. Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9:364–77.PubMed Hines LE, Murphy JE. Potentially harmful drug–drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9:364–77.PubMed
10.
Zurück zum Zitat Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opin Drug Saf. 2012;11:83–94.PubMed Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactions. Expert Opin Drug Saf. 2012;11:83–94.PubMed
11.
Zurück zum Zitat Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.PubMedPubMedCentral Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–9.PubMedPubMedCentral
12.
Zurück zum Zitat Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489–97.PubMed Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug–drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489–97.PubMed
13.
Zurück zum Zitat Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4:e4439.PubMedPubMedCentral Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009;4:e4439.PubMedPubMedCentral
14.
Zurück zum Zitat Kovacevic M, VezmarKovacevic S, Radovanovic S, Stevanovic P, Miljkovic B. Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. Curr Med Res Opin. 2019;35:1873–83.PubMed Kovacevic M, VezmarKovacevic S, Radovanovic S, Stevanovic P, Miljkovic B. Adverse drug reactions caused by drug–drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. Curr Med Res Opin. 2019;35:1873–83.PubMed
15.
Zurück zum Zitat Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641–51.PubMed Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug–drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641–51.PubMed
16.
Zurück zum Zitat KrahenbuhlMelcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30:379–407. KrahenbuhlMelcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30:379–407.
17.
Zurück zum Zitat Alvim MM, Silva LA, Leite IC, Silverio MS. Adverse events caused by potential drug–drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva. 2015;27:353–9.PubMedPubMedCentral Alvim MM, Silva LA, Leite IC, Silverio MS. Adverse events caused by potential drug–drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva. 2015;27:353–9.PubMedPubMedCentral
18.
Zurück zum Zitat Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug–drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74:15–27.PubMed Zheng WY, Richardson LC, Li L, Day RO, Westbrook JI, Baysari MT. Drug–drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74:15–27.PubMed
19.
Zurück zum Zitat Cecchi E. Drug–drug interaction knowledge to save the patient from iatrogenic disease and to improve the diagnostic process. Intern Emerg Med. 2019;14:345–7.PubMed Cecchi E. Drug–drug interaction knowledge to save the patient from iatrogenic disease and to improve the diagnostic process. Intern Emerg Med. 2019;14:345–7.PubMed
20.
Zurück zum Zitat Alshammari TM. Drug safety: the concept, inception and its importance in patients' health. Saudi Pharm J. 2016;24:405–12.PubMed Alshammari TM. Drug safety: the concept, inception and its importance in patients' health. Saudi Pharm J. 2016;24:405–12.PubMed
21.
Zurück zum Zitat Mugosa S, Bukumiric Z, Kovacevic A, Boskovic A, Protic D, Todorovic Z. Adverse drug reactions in hospitalized cardiac patients: characteristics and risk factors. Vojnosanit Pregl. 2015;72:975–81.PubMed Mugosa S, Bukumiric Z, Kovacevic A, Boskovic A, Protic D, Todorovic Z. Adverse drug reactions in hospitalized cardiac patients: characteristics and risk factors. Vojnosanit Pregl. 2015;72:975–81.PubMed
22.
Zurück zum Zitat Klopotowska JE, Wierenga PC, Smorenburg SM, Stuijt CC, Arisz L, Kuks PF, et al. Recognition of adverse drug events in older hospitalized medical patients. Eur J Clin Pharmacol. 2013;69:75–85.PubMed Klopotowska JE, Wierenga PC, Smorenburg SM, Stuijt CC, Arisz L, Kuks PF, et al. Recognition of adverse drug events in older hospitalized medical patients. Eur J Clin Pharmacol. 2013;69:75–85.PubMed
23.
Zurück zum Zitat Kovacevic M, Kovacevic SV, Miljkovic B, Radovanovic S, Stevanovic P. The prevalence and preventability of potentially relevant drug–drug interactions in patients admitted for cardiovascular diseases: a cross-sectional study. Int J Clin Pract. 2017;71:e13005. Kovacevic M, Kovacevic SV, Miljkovic B, Radovanovic S, Stevanovic P. The prevalence and preventability of potentially relevant drug–drug interactions in patients admitted for cardiovascular diseases: a cross-sectional study. Int J Clin Pract. 2017;71:e13005.
24.
Zurück zum Zitat Roblek T, Trobec K, Mrhar A, Lainscak M. Potential drug–drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci. 2014;10:920–32.PubMedPubMedCentral Roblek T, Trobec K, Mrhar A, Lainscak M. Potential drug–drug interactions in hospitalized patients with chronic heart failure and chronic obstructive pulmonary disease. Arch Med Sci. 2014;10:920–32.PubMedPubMedCentral
25.
Zurück zum Zitat Urbina O, Ferrandez O, Luque S, Grau S, Mojal S, Pellicer R, et al. Patient risk factors for developing a drug-related problem in a cardiology ward. Ther Clin Risk Manag. 2015;11:9–15.PubMed Urbina O, Ferrandez O, Luque S, Grau S, Mojal S, Pellicer R, et al. Patient risk factors for developing a drug-related problem in a cardiology ward. Ther Clin Risk Manag. 2015;11:9–15.PubMed
26.
Zurück zum Zitat Marusic S, Bacic-Vrca V, ObreliNeto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug–drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69:1717–24.PubMed Marusic S, Bacic-Vrca V, ObreliNeto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug–drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69:1717–24.PubMed
27.
Zurück zum Zitat Kongkaew C, Hann M, Mandal J, Williams SD, Metcalfe D, Noyce PR, et al. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy. 2013;33:827–37.PubMed Kongkaew C, Hann M, Mandal J, Williams SD, Metcalfe D, Noyce PR, et al. Risk factors for hospital admissions associated with adverse drug events. Pharmacotherapy. 2013;33:827–37.PubMed
28.
Zurück zum Zitat Davies EA, O'Mahony MS. Adverse drug reactions in special populations—the elderly. Br J Clin Pharmacol. 2015;80:796–807.PubMedPubMedCentral Davies EA, O'Mahony MS. Adverse drug reactions in special populations—the elderly. Br J Clin Pharmacol. 2015;80:796–807.PubMedPubMedCentral
29.
Zurück zum Zitat Marino A, Capogrosso-Sansone A, Tuccori M, Bini G, Calsolaro V, Mantarro S, et al. Expected and actual adverse drug–drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study. Expert Opin Drug Saf. 2016;15:45–50.PubMed Marino A, Capogrosso-Sansone A, Tuccori M, Bini G, Calsolaro V, Mantarro S, et al. Expected and actual adverse drug–drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study. Expert Opin Drug Saf. 2016;15:45–50.PubMed
30.
Zurück zum Zitat Wilbur K, Hazi H, ElBedawi A. Drug-related hospital visits and admissions associated with laboratory or physiologic abnormalities—a systematic-review. PLoS ONE. 2013;8:e66803.PubMedPubMedCentral Wilbur K, Hazi H, ElBedawi A. Drug-related hospital visits and admissions associated with laboratory or physiologic abnormalities—a systematic-review. PLoS ONE. 2013;8:e66803.PubMedPubMedCentral
31.
Zurück zum Zitat Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309–21.PubMed Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309–21.PubMed
32.
Zurück zum Zitat Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, et al. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017;103:1536–42.PubMed Brook RD, Anderson JA, Calverley PM, Celli BR, Crim C, Denvir MA, et al. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017;103:1536–42.PubMed
34.
Zurück zum Zitat Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16:2119–266.PubMed Navarro JF, Mora C, Muros M, Garcia J. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial. J Am Soc Nephrol. 2005;16:2119–266.PubMed
35.
Zurück zum Zitat Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis. 2008;52:464–74.PubMed Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis. 2008;52:464–74.PubMed
36.
Zurück zum Zitat Goicoechea M, de Vinuesa SG, Quiroga B, Verdalles U, Barraca D, Yuste C, et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol. 2012;25:969–75.PubMed Goicoechea M, de Vinuesa SG, Quiroga B, Verdalles U, Barraca D, Yuste C, et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol. 2012;25:969–75.PubMed
37.
Zurück zum Zitat Rodriguez-Moran M, Gonzalez-Gonzalez G, Bermudez-Barba MV, de la Garza CEM, TamezPerez HE, Martinez-Martinez FJ, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin Nephrol. 2006;66:3–10.PubMed Rodriguez-Moran M, Gonzalez-Gonzalez G, Bermudez-Barba MV, de la Garza CEM, TamezPerez HE, Martinez-Martinez FJ, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial. Clin Nephrol. 2006;66:3–10.PubMed
38.
Zurück zum Zitat Maiti R, Agrawal NK, Dash D, Pandey BL. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol. 2007;47:118–24.PubMed Maiti R, Agrawal NK, Dash D, Pandey BL. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol. 2007;47:118–24.PubMed
39.
Zurück zum Zitat Navarro-Gonzalez JF, Muros M, Mora-Fernandez C, Herrera H, Meneses B, Garcia J. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. J Diabetes Complications. 2011;25:314–9.PubMed Navarro-Gonzalez JF, Muros M, Mora-Fernandez C, Herrera H, Meneses B, Garcia J. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results. J Diabetes Complications. 2011;25:314–9.PubMed
40.
Zurück zum Zitat DiPetrillo K, Gesek FA. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol. 2004;24:352–9.PubMed DiPetrillo K, Gesek FA. Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol. 2004;24:352–9.PubMed
41.
Zurück zum Zitat Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67:1181–8.PubMed Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67:1181–8.PubMed
42.
Zurück zum Zitat Geerts AF, De Koning FH, De Smet PA, Van Solinge WW, Egberts TC. Laboratory tests in the clinical risk management of potential drug–drug interactions: a cross-sectional study using drug-dispensing data from 100 Dutch community pharmacies. Drug Saf. 2009;32:1189–97.PubMed Geerts AF, De Koning FH, De Smet PA, Van Solinge WW, Egberts TC. Laboratory tests in the clinical risk management of potential drug–drug interactions: a cross-sectional study using drug-dispensing data from 100 Dutch community pharmacies. Drug Saf. 2009;32:1189–97.PubMed
43.
Zurück zum Zitat Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.PubMed Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.PubMed
44.
Zurück zum Zitat Bykov K, Gagne JJ. Generating evidence of clinical outcomes of drug–drug interactions. Drug Saf. 2017;40:101–3.PubMed Bykov K, Gagne JJ. Generating evidence of clinical outcomes of drug–drug interactions. Drug Saf. 2017;40:101–3.PubMed
Metadaten
Titel
Potential drug–drug interactions associated with clinical and laboratory findings at hospital admission
verfasst von
Milena Kovačević
Sandra Vezmar Kovačević
Slavica Radovanović
Predrag Stevanović
Branislava Miljković
Publikationsdatum
21.12.2019
Verlag
Springer International Publishing
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 1/2020
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-019-00951-y

Weitere Artikel der Ausgabe 1/2020

International Journal of Clinical Pharmacy 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.